Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.

Autor: Calise J; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., DeBerg H; Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Garabatos N; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Khosa S; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Bajzik V; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Calderon LB; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Aldridge K; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Rosasco M; Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Ferslew BC; Astellas Pharma Global Development Inc, Northbrook, Ill., Zhu T; Astellas Pharma Global Development Inc, Northbrook, Ill., Smulders R; Astellas Pharma Global Development Inc, Northbrook, Ill., Wheatley LM; National Institute of Allergy and Infectious Diseases, Bethesda, Md., Laidlaw TM; Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash; Department of Medicine, Harvard Medical School, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass., Qin T; Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Chichili GR; Astellas Pharma Global Development Inc, Northbrook, Ill., Adelman DC; Aimmune Therapeutics, Brisbane, Calif., Farrington M; Virginia Mason Medical Center, Seattle, Wash., Robinson D; Virginia Mason Medical Center, Seattle, Wash., Jeong D; Virginia Mason Medical Center, Seattle, Wash., Jones SM; Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Ark., Sanda S; Immune Tolerance Network, UCSF Diabetes Center & UCSF School of Medicine, San Francisco, Calif., Larson D; Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Kwok WW; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Baloh C; Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash; Department of Medicine, Harvard Medical School, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass., Nepom GT; Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash., Wambre E; Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Wash. Electronic address: ewambre@benaroyaresearch.org.

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2023 Jul; Vol. 152 (1), pp. 155-166.e9. Date of Electronic Publication: 2023 Mar 30.

Poisonings with malicious or criminal intent in the emergency department.

Autor: Chih-Yang Mao¹, Lu-Chen Chen¹, Yen-Chia Chen^2,3, Chia-Hung Lin⁴, Shi-Ying Gao¹, Wei-Chen Chen¹, Tzung-Hai Yen^5,6, Hsien-Yi Chen^1,6 m7082@cgmh.org.tw

Publikováno v: Signa Vitae. Oct2024, Vol. 20 Issue 10, p30-37. 8p.

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Autor: Ferslew, BC, Johnston, CK, Tsakalozou, E, Bridges, AS, Paine, MF, Jia, W, Stewart, PW, Barritt, AS, Brouwer, KLR

Publikováno v: Clinical Pharmacology & Therapeutics; Apr2015, Vol. 97 Issue 4, p419-427, 9p

Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.

Autor: Wells MA; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Vendrov KC; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Edin ML; Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States., Ferslew BC; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Zha W; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Nguyen BK; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Church RJ; University of North Carolina Institute for Drug Safety Sciences, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Lih FB; Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States., DeGraff LM; Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States., Brouwer KL; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Barritt AS 4th; Division of Gastroenterology and Hepatology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Zeldin DC; Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States., Lee CR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Electronic address: craig_lee@unc.edu.

Publikováno v: Prostaglandins & other lipid mediators [Prostaglandins Other Lipid Mediat] 2016 Sep; Vol. 125, pp. 19-29. Date of Electronic Publication: 2016 Jul 09.

Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.

Autor: Ferslew BC; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Kerr Hall, CB #7569, Chapel Hill, NC, 27599, USA. bferslew@theravance.com.; Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., 901 Gateway Blvd, South San Francisco, CA, 94080, USA. bferslew@theravance.com., Xie G; Metabolomics Shared Resource, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA. GXie@cc.hawaii.edu., Johnston CK; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Kerr Hall, CB #7569, Chapel Hill, NC, 27599, USA. curtis.k.johnston@gmail.com., Su M; Metabolomics Shared Resource, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA. MSu@cc.hawaii.edu., Stewart PW; Department of Biostatistics, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 3105G McGavran-Greenberg Hall, Chapel Hill, NC, 27599, USA. Paul_Stewart@unc.edu., Jia W; Metabolomics Shared Resource, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI, 96813, USA. WJia@cc.hawaii.edu., Brouwer KL; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Kerr Hall, CB #7569, Chapel Hill, NC, 27599, USA. kbrouwer@unc.edu., Barritt AS 4th; Division of Gastroenterology and Hepatology, UNC School of Medicine, University of North Carolina at Chapel Hill, 8004 Burnett Womack, CB #7584, Chapel Hill, NC, 27599-7584, USA. sid_barritt@med.unc.edu.

Publikováno v: Digestive diseases and sciences [Dig Dis Sci] 2015 Nov; Vol. 60 (11), pp. 3318-28. Date of Electronic Publication: 2015 Jul 03.